Per Wester, Chief Executive Officer. Per Wester joined Alzinova as CEO on September 30, 2015. Before joining Alzinova, Wester was CEO of Mundipharma AB (a Swedish subsidiary of the Purdue/Mundipharma/Napp Group) for 17 years and General Manager Nordic Region since 2011. He was during 2014-15 also a member of the Board of the Research-Based Pharmaceutical Industry in Sweden (LIF).
For more information, please contact Per at email@example.com, or by phone at +46 708 374 433.
Anders Sandberg, Chief Scientific Officer. PhD. Board alternate and co-founder of Alzinova. Anders brings over 16 years of protein research to the board, with special emphasis on neurotoxic peptide aggregates for the last 9 years. He is also co-inventor of Alzinova’s AβCC peptide™ technology.
Andreas Blom, Chief Financial Officer and board alternate. MBA. Andreas has many years experience working as an auditor within EY. He has also been deeply involved in many start-up companies as CFO.